Copyright 2026 All rights reserved.

About bHLBIO

bHLBIO develops the innovative drug for the healthy human life, using our novel CUPID platform
which can monitor in real time the Protein-Protein Interaction (PPI) in living cell.

History

Under our management philosophy of improving the health of mankind,
bHLBIO is committed to developing new drugs based on innovative platform technologies.

MANAGEMENT
For Better Human Life
  • 2022
    • Attracted an additional 200 million KRW in angel investments
    • K-BIO advanced medical technology value creation project
      Preliminary selection for Osong Medical Innovation Foundation Task
    • TIPS start-up commercialization
      Preliminary selection for tasks by the Ministry of SMEs & Startups
  • 2021
    • Attracted 800 million KRW in angel investments
    • Certified as a venture enterprise
    • Established a Strategic Planning Division
    • Inaugurated Mr. Han Sung-jun
      as new the CEO
    • Changed the company name to bHLBIO
  • 2020
  • 2019
    • Established Probon Bio
    • Attracted 600 million KRW for TIPS
      - 100 million KRW
      investment from Medytox Venture
      - 500 million KRW
      from government subsidies
    • KBSI Family Enterprise
DEVELOPMENT
Innovative PPI Technology
  • 2022
    • CUPID Screening Service
      Olive Bio Therapeutics
    • Derived KRAS targeted anti-cancer drug candidates
    • Initiated animal testing for KRAS-targeted anti-cancer drugs
    • CUPID screening service
  • 2021
    • KRAS targeted candidate substance
      Set-up a screening system.
    • Expanded the Myc-Max targeted pipeline
    • KRAS targeted anti-cancer drug
      Derived candidate substance
      (Drug re-purposing)
  • 2020
    • Optimized and advanced the CUPID platform technology
    • CUPID screening service - Curex
    • Expanded the REV PPI targeted pipeline
  • 2019
    • Adopted CUPID technology
    • CUPID screening service
      Cowell Biodigm